Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: luis a. garcia who wrote (700)	11/10/1997 4:24:00 PM
From: luis a. garcia	Read Replies (1) \| Respond to of 1115

The stock is lost all momemtum... what a drag. It was going so well too. bummer... I guess we need to wait for the next event... luis

To: luis a. garcia who wrote (700)	11/11/1997 9:59:00 AM
From: MCorbley	Read Replies (1) \| Respond to of 1115

Luis, Charles Glad to be of service. I forgot to add another thought about Lidakol's competitors: In a head-to-head clinical trial in Europe, Lidakol compared favorably with Zovirax 5% cream for treatment of cold sores. Zovirax 5% cream is better than anything available in the U.S., in particular Zovirax 5% ointment. Yamanouchi has invested a great deal of money and effort in testing and developing Lidakol for the European market. Therefore they must believe that there is still an unaddressed need for Lidakol and a market for Lidakol even in Europe despite the availability of Zovirax cream. Michael